ALS Canada Rallies Around Progress in Research and a Call for Continued Action This ALS Awareness Month

Why It Matters

Sustained funding and public advocacy are critical to expanding clinical trials and delivering new therapies that can extend life and improve quality of care for ALS patients across Canada.

Key Takeaways

• Qalsody approved 2025, slows progression for SOD1‑ALS patients.
• ALS Canada lobbied for Canadian Collaboration to Cure ALS funding.
• Walk to End ALS events in 22 Ontario communities start June 6.
• Triple‑matched donations up to CAD 5,000 (~US $3,700) this June.
• Over 4,000 Canadians live with ALS; 1,000 new diagnoses yearly.

Pulse Analysis

Amyotrophic lateral sclerosis (ALS) remains one of the most aggressive neurodegenerative diseases, affecting roughly one in 300 Canadians over a lifetime. With about 4,000 individuals currently living with ALS and an annual influx of 1,000 new diagnoses, the condition typically shortens life expectancy to two‑to‑five years post‑diagnosis. The rapid loss of motor function forces patients and families into costly care pathways, highlighting a pressing need for both therapeutic breakthroughs and robust support services.

In 2025, Health Canada granted approval to Qalsody (tofersen), the first disease‑modifying therapy for the SOD1 genetic form of ALS. While not a cure, the drug demonstrably slows disease progression, validating the impact of targeted research investment. ALS Canada played a pivotal role in nurturing the scientific groundwork that led to this milestone and is now championing the Canadian Collaboration to Cure ALS, a federal initiative aimed at scaling research capacity, expanding trial access, and accelerating discovery across the nation.

June’s awareness campaign translates scientific hope into community action. The Walk to End ALS will span 22 Ontario locales, while a triple‑matched donation program—up to CAD 5,000 (approximately US $3,700)—offers donors amplified impact. High‑visibility events such as the Toronto Blue Jays’ Lou Gehrig Day and nationwide "Light It Purple" landmarks amplify public consciousness. By converting this momentum into sustained funding, ALS Canada seeks to ensure that emerging therapies like Qalsody become widely accessible and that future innovations continue to move the ALS community closer to a world without the disease.